Pacira Pharmaceuticals reported $8.83M in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Acelrx Pharmaceuticals ACRX:US $ 390K 77K
Aerie Pharmaceuticals AERI:US $ 1.64M 0M
Amerisourcebergen ABC:US $ 57.66M 2.28M
Bristol Myers Squibb BMY:US $ 313M 13M
Depomed DEPO:US $ 2.33M 0.11M
Endo International Ordinary Shares ENDP:US $ 135.07M 8.53M
Ironwood Pharmaceuticals IRWD:US $ 2.21M 0.13M
Lannett LCI:US $ 14.52M 0.09M
Ligand Pharmaceuticals LGND:US $ 0.79M 3.68M
Nektar Therapeutics NKTR:US $ 7.23M 0.3M
Omeros OMER:US $ 4.94M 10K
Pacira Pharmaceuticals PCRX:US $ 8.83M 1.41M
Pfizer PFE:US $ 293M 29M
Revance Therapeutics RVNC:US $ 1.93M 358K
Supernus Pharmaceuticals SUPN:US $ 1.81M 0.66M
Teva Pharmaceutical TEVA:IT 225M 13M
Xeris Pharmaceuticals Inc XERS:US $ 3.52M 1.72M
Xoma XOMA:US $ 0 0
Zoetis ZTS:US $ 53M 0M